Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

IL-2 antibodies in type 1 diabetes and during IL-2 therapy

(2018) Guillaume Churlaud et al.   DIABETOLOGIA

Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2

(2018) Guillaume Churlaud et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses

(2018) Fabien Pitoiset et al.   CYTOMETRY PART A

Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin-2

(2017) Denis Comte et al.   Arthritis & Rheumatology

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells

(2016) Marco De Simone et al.   IMMUNITY

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

(2016) Jing He et al.   NATURE MEDICINE

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

(2015) Caroline von Spee-Mayer et al.   ANNALS OF THE RHEUMATIC DISEASES

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

(2015) Aixin Yu et al.   DIABETES

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

(2015) Michelle Rosenzwajg et al.   JOURNAL OF AUTOIMMUNITY

Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases

(2015) Yun R Li et al.   NATURE MEDICINE

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy

(2014) F. Van Gool et al.   BLOOD

Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity

(2014) A. A. Kennedy-Nasser et al.   CLINICAL CANCER RESEARCH

Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers

(2014) Sawa Ito et al.   MOLECULAR THERAPY

Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata

(2014) Emeline Castela et al.   JAMA Dermatology

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

(2013) K.-i. Matsuoka et al.   Science Translational Medicine

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

(2013) Agnès Hartemann et al.   Lancet Diabetes & Endocrinology

Interleukin-2 Inhibits Germinal Center Formation by Limiting T Follicular Helper Cell Differentiation

(2012) André Ballesteros-Tato et al.   IMMUNITY

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

The IL-2 Defect in Systemic Lupus Erythematosus Disease Has an Expansive Effect on Host Immunity

(2010) Linda A. Lieberman et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

(2009) Kajsa Wing et al.   NATURE IMMUNOLOGY